PRIMARY STUDY

Systematic review of the potential role of cannabinoids as antiproliferative agents for urological cancers

Key Findings:  Although many studies have explored the in vitro mechanisms and population-based evidence for cannabinoids, there have been no clinical trials to date for urological cancer patients. Currently, there is no conclusive evidence to support patient claims for starting on cannabinoid monotherapy for anticancer benefit when all other avenues for therapy have failed.